Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method.

Z Mesbahi, H Kabbaj, H Malki, N Bouihat, M Qrafli, B Belefquih, S Marcil, Dominique CHALLINE, Jean-Michel PAWLOTSKY, Magali BOUVIER-ALIAS, M Seffar,

J Med Virol. 01/08/2018;90(8) : 1352-1357 10.1002/jmv.25191 26/04/2018

The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.

AD Marshall, Jean-Michel PAWLOTSKY, JV Lazarus, A Aghemo, GJ Dore, J Grebely,

J Hepatol. 28/06/2018;pii: S0168-8278(18) : 32169-X 10.1016/j.jhep.2018.06.016

Characterization of the anti-hepatitis C virus activity of new non-peptidic small-molecule cyclophilin inhibitors with a potential for broad anti-Flaviviridae activity.

Quentin NEVERS, Isaac RUIZ, Nazim AHNOU, F Donati, Rozenn BRILLET, Laurent SOFTIC, M Chazal, N Jouvenet, Slim FOURATI, Camille BAUDESSON, Patrice BRUSCELLA, M Gelin, JF Guichou, Jean-Michel PAWLOTSKY, Abdelhakim AHMED-BELKACEM,

Antimicrob Agents Chemother. 14/05/2018;AAC : 00126-18 10.1128/AAC.00126-18

Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE

V De Ledinghen, C Laforest, Christophe HEZODE, S Pol, A Renault, L Alric, D Larrey, S Metivier, A Tran, C Jezequel, D Samuel, F Zoulim, C Tual, A Pailhe, S Gibowski, M Bourliere, E Bellissant, Jean-Michel PAWLOTSKY,

Clin Infect Dis. 19/03/2018;66(7) : 1013-1018 10.1093/cid/cix916.

Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study

V De Ledinghen, C Laforest, Christophe HEZODE, S Pol, A Renault, L Alric, D Larrey, S Metivier, A Tran, C Jezequel, D Samuel, F Zoulim, C Tual, A Pailhe, S Gibowski, M Bourliere, E Bellissant, Jean-Michel PAWLOTSKY,

Clin Infect Dis. 19/03/2018;66(7) : 1013-1018 10.1093/cid/cix916.

A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination.

Christophe RODRIGUEZ, Alexandre SOULIER, Vanessa DEMONTANT, Lila POITEAU, Mélanie MERCIER-DARTY, Magali BOUVIER-ALIAS, Jean-Michel PAWLOTSKY, Stephane CHEVALIEZ,

Sci Rep. 08/03/2018;8(1) : 4180 10.1038/s41598-018-22614-0.

Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor

Slim FOURATI, J Guedj, Stephane CHEVALIEZ, THT Nguyen, F Roudot-Thoraval, Isaac RUIZ, Alexandre SOULIER, G Scoazec, A Varaut, Lila POITEAU, Murielle FRANCOIS, A Mallat, Christophe HEZODE, Jean-Michel PAWLOTSKY,

Aliment Pharmacol Ther. 01/03/2018;47(5) : 665-673 10.1111/apt.14478. 22/12/2017

Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations? Authors' reply.

Slim FOURATI, Jean-Michel PAWLOTSKY,

Aliment Pharmacol Ther. 01/03/2018;47(6) : 849-850 10.1111/apt.14520.

Interleukins-17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation

A Guillot, Imène GASMI, Arthur BROUILLET, Y Ait-Ahmed, Julien CALDERARO, Isaac RUIZ, B Gao, S Lotersztajn, Jean-Michel PAWLOTSKY, Fouad LAFDIL,

Hepatol Commun. 30/01/2018;2(3) : 329-343 10.1002/hep4.1145.

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage

AH Talal, EO Dumas, B Bauer, RM Rejman, A Ocque, GD Morse, D Lucic, G Cloherty, J King, J Zha, H Zhang, DE Cohen, NS Shulman, Jean-Michel PAWLOTSKY, Christophe HEZODE,

J Infect Dis 17/01/2018;217(3) : 474-482 10.1093/infdis/jix495.